目的探讨肝硬变患者血浆生长抑素变化的意义．方法用ＲＩＡ法测定临床诊断为肝硬变的患者４９例和正常对照者３６例，空腹血浆生长抑素（ＳＳ）含量，对肝硬变患者行内镜检查，并检测甲胎蛋白（ＡＦＰ）、透明质酸（ＨＡ）、甘胆酸（ＣＧ）等．分析肝硬变及其不同并发症时ＳＳ的变化．结果血浆ＳＳ含量（ｎｇ／Ｌ）在肝硬变Ｂ级组（２２例）为４７１±２２０，Ｃ级组（２７例）为６６０±３３５；对照组为６１２±１７０．Ｂ级组与Ｃ级组及正常对照组比较Ｐ＜００１．肝硬变并发肝癌及肝肾综合征患者的ＳＳ水平分别为９３８±２７１和９３３±１１７，与无肝癌（４８２±２３２）及无肝肾综合征组（５５１±２９６）比较，Ｐ＜００１．血浆ＳＳ浓度在肝硬变有食管静脉曲张（ＥＶ），胃粘膜病变（ＧＭＬ）及出血组分别为５１２±３００，４１２±２１２及４３０．±２１７，与无ＥＶ（７３１±２５７）、无ＧＭＬ（６６２±３０９）及无出血组（６２７±３１３）相比均显著降低（Ｐ＜００５）．ＳＳ与ＡＦＰ呈正相关（ｒ＝０４３９，Ｐ＜００１）．结论肝硬变时血浆ＳＳ的变化与肝硬变多种并发症的出现有关；ＳＳ增高有可能作为肝硬变并? Objective To investigate the significance of plasma somatostatin in cirrhotic patients. Methods 49 patients with cirrhosis and 36 patients with normal liver cirrhosis were determined by RIA method. The fasting plasma somatostatin (SS) content was determined. Endoscopy was performed on patients with cirrhosis and AFP (AFP) , Hyaluronic acid (HA), glycocholic acid (CG) and the like. Analysis of cirrhosis and its different complications SS changes. Results The level of plasma SS (ng / L) was 471 ± 220 in group B (22 cases) and 660 ± 335 in group C (61 cases) 2 ± 170. B grade group and C grade group and normal control group P <0  01. The levels of SS in cirrhotic patients with hepatocellular carcinoma and hepatorenal syndrome were 938 ± 271 and 933 ± 117, respectively, which were significantly higher than those without hepatocellular carcinoma (482 ± 232) and without hepatorenal syndrome Group (551 ± 296), P <001. The level of plasma SS in patients with cirrhosis with esophageal varices (EV), gastric mucosal lesions (GML) and hemorrhage were 512 ± 300, 412 ± 212 and 430, respectively. ± 217 were significantly lower than those without EV (731 ± 257), without GML (662 ± 309) and without bleeding (627 ± 313) (P < 0  05). SS and AFP were positively correlated (r = 0439, P <001). Conclusions The changes of plasma SS in cirrhotic patients are related to the occurrence of various complications of cirrhosis. SS may be associated with liver cirrhosis.